Enterprise Value
13.9B
Cash
1.211B
Avg Qtr Burn
N/A
Short % of Float
2.64%
Insider Ownership
1.01%
Institutional Own.
95.88%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
INGREZZA (valbenazine) Details Huntington's disease, Dyskinesia | Approved Quarterly sales | |
INGREZZA (valbenazine) Details Chorea, Huntington's disease, Dyskinesia | Approved Quarterly sales | |
INGREZZA (valbenazine) Details Huntington's disease, Chorea | Approved Quarterly sales | |
Crinecerfont [oral solution] Details Congenital adrenal hyperplasia | PDUFA Approval decision | |
Crinecerfont [capsule] Details Congenital adrenal hyperplasia | PDUFA Approval decision | |
Valbenazine Details Neurological disorder, Cerebral Palsy, Dyskinesia | Phase 3 Data readout | |
Valbenazine Details Psychiatric disorder, Schizophrenia | Phase 3 Data readout | |
NBI-1070770 (NMDA NR2B Negative Allosteric Modulator) Details Major depressive disorder | Phase 2 Data readout | |
Luvadaxistat Details Psychiatric disorder, Schizophrenia | Phase 2 Data readout | |
NBI-1117568 Details Schizophrenia | Phase 2 Data readout | |
Chronocort® (Efmody) Details Adrenal Insufficiency | Phase 2 Update | |
NBI-1065846 Details Major depressive disorder | Phase 2 Update | |
NBI-1065845 Details Major depressive disorder | Phase 2 Update | |
Efmody Details Congenital adrenal hyperplasia | Phase 2 Update | |
NBI-921352 Details Focal Onset Seizures | Phase 2 Update | |
NBI-1076986 Details Parkinson's disease, Dystonia (Blepharospasm) | Phase 1 Data readout | |
NBI-1117570 (Dual M1/M4 Agonist) Details Schizophrenia | Phase 1 Data readout | |
NBI-1117567 Details Neurological disorder, Psychiatric disorder | Phase 1 Data readout | |
NBI-1065890 Details Neurological disorder | Phase 1 Data readout |